{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,31]],"date-time":"2026-05-31T08:00:39Z","timestamp":1780214439281,"version":"3.54.0"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,5,31]]},"DOI":"10.7759\/cureus.109953","type":"journal-article","created":{"date-parts":[[2026,5,31]],"date-time":"2026-05-31T07:09:32Z","timestamp":1780211372000},"source":"Crossref","is-referenced-by-count":0,"title":["Incretin-Based Therapies in Obesity-Related Heart Failure With Preserved Ejection Fraction (HFpEF): A Systematic Review of Emerging Cardiometabolic Disease Modification Beyond Glycemic Control"],"prefix":"10.7759","author":[{"given":"Vaishnavi","family":"Hemdev","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad","family":"Abuzenah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qossay","family":"Alsaafin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zaid","family":"Al Ghananeem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fnu","family":"Diksha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adnan","family":"Khatak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.3390\/jcm14248781","article-title":"Heart failure with preserved ejection fraction (HFpEF), pulse wave velocity, and heart rate recovery interconnections-a brief literature review","volume":"14","author":"Suciu BS","year":"2025","unstructured":"Suciu BS, Turi VR, Crisan S, et al.. Heart failure with preserved ejection fraction (HFpEF), pulse wave velocity, and heart rate recovery interconnections-a brief literature review. J Clin Med. 2025, 14:10.3390\/jcm14248781","journal-title":"J Clin Med"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.2147\/VHRM.S578698","article-title":"Clinical advances in heart failure with preserved ejection fraction: a systematic review of therapeutic and mechanistic evidence","volume":"22","author":"Parizad R","year":"2026","unstructured":"Parizad R, Hatwal J, Taban Sadeghi M, Brar A, Desai R, Batta A, Mohan B. Clinical advances in heart failure with preserved ejection fraction: a systematic review of therapeutic and mechanistic evidence. Vasc Health Risk Manag. 2026, 22:578698. 10.2147\/VHRM.S578698","journal-title":"Vasc Health Risk Manag"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2023.01.049","article-title":"Heart failure with preserved ejection fraction: JACC scientific statement","volume":"81","author":"Borlaug BA","year":"2023","unstructured":"Borlaug BA, Sharma K, Shah SJ, Ho JE. Heart failure with preserved ejection fraction: JACC scientific statement. J Am Coll Cardiol. 2023, 81:1810-34. 10.1016\/j.jacc.2023.01.049","journal-title":"J Am Coll Cardiol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.81512","article-title":"Obesity-related phenotype of heart failure with preserved ejection fraction: a comprehensive review","volume":"17","author":"El Hadj Othmane T","year":"2025","unstructured":"El Hadj Othmane T, El Hadj Othmane O, Nizar H. Obesity-related phenotype of heart failure with preserved ejection fraction: a comprehensive review. Cureus. 2025, 17:e81512. 10.7759\/cureus.81512","journal-title":"Cureus"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1186\/s12933-025-02774-w","article-title":"Cardiometabolic heart failure with preserved ejection fraction: from molecular signatures to personalized treatment","volume":"24","author":"Gorica E","year":"2025","unstructured":"Gorica E, Geiger MA, Di Venanzio L, et al.. Cardiometabolic heart failure with preserved ejection fraction: from molecular signatures to personalized treatment. Cardiovasc Diabetol. 2025, 24:265. 10.1186\/s12933-025-02774-w","journal-title":"Cardiovasc Diabetol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.3390\/diabetology7030046","article-title":"Incretin-based multi-agonist therapies for type 2 diabetes mellitus and obesity: mechanisms, clinical efficacy, and future directions","volume":"7","author":"Podder D","year":"2026","unstructured":"Podder D, Stala O, Miah A, et al.. Incretin-based multi-agonist therapies for type 2 diabetes mellitus and obesity: mechanisms, clinical efficacy, and future directions. Diabetology. 2026, 7:46. 10.3390\/diabetology7030046","journal-title":"Diabetology"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.3390\/medsci13040269","article-title":"Incretin-based therapies through the decades: molecular innovations and clinical impact","volume":"13","author":"Lee AA","year":"2025","unstructured":"Lee AA, Khotina VA, Kashirskikh DA, Voronko OE, Gasanov VA, Vasiliev AV. Incretin-based therapies through the decades: molecular innovations and clinical impact. Med Sci (Basel). 2025, 13:10.3390\/medsci13040269","journal-title":"Med Sci (Basel)"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1093\/eschf\/xvag042","article-title":"Semaglutide vs tirzepatide in patients with obesity and HFpEF: a report from a global federated research network","volume":"13","author":"Monzo L","year":"2026","unstructured":"Monzo L, Savarese G, Duarte K, Baudry G, Petrie MC, Girerd N. Semaglutide vs tirzepatide in patients with obesity and HFpEF: a report from a global federated research network. ESC Heart Fail. 2026, 13:10.1093\/eschf\/xvag042","journal-title":"ESC Heart Fail"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page MJ","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, et al.. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021, 372:n71. 10.1136\/bmj.n71","journal-title":"BMJ"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne JA","year":"2019","unstructured":"Sterne JA, Savovi\u0107 J, Page MJ, et al.. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019, 366:l4898. 10.1136\/bmj.l4898","journal-title":"BMJ"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2306963","article-title":"Semaglutide in patients with heart failure with preserved ejection fraction and obesity","volume":"389","author":"Kosiborod MN","year":"2023","unstructured":"Kosiborod MN, Abildstr\u00f8m SZ, Borlaug BA, et al.. Semaglutide in patients with heart failure with preserved ejection fraction and obesity. N Engl J Med. 2023, 389:1069-84. 10.1056\/NEJMoa2306963","journal-title":"N Engl J Med"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2313917","article-title":"Semaglutide in patients with obesity-related heart failure and type 2 diabetes","volume":"390","author":"Kosiborod MN","year":"2024","unstructured":"Kosiborod MN, Petrie MC, Borlaug BA, et al.. Semaglutide in patients with obesity-related heart failure and type 2 diabetes. N Engl J Med. 2024, 390:1394-407. 10.1056\/NEJMoa2313917","journal-title":"N Engl J Med"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(24)00469-0","article-title":"Semaglutide versus placebo in people with obesity-related heart failure with preserved ejection fraction: a pooled analysis of the STEP-HFpEF and STEP-HFpEF DM randomised trials","volume":"403","author":"Butler J","year":"2024","unstructured":"Butler J, Shah SJ, Petrie MC, et al.. Semaglutide versus placebo in people with obesity-related heart failure with preserved ejection fraction: a pooled analysis of the STEP-HFpEF and STEP-HFpEF DM randomised trials. Lancet. 2024, 403:1635-48. 10.1016\/S0140-6736(24)00469-0","journal-title":"Lancet"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2410027","article-title":"Tirzepatide for heart failure with preserved ejection fraction and obesity","volume":"392","author":"Packer M","year":"2025","unstructured":"Packer M, Zile MR, Kramer CM, et al.. Tirzepatide for heart failure with preserved ejection fraction and obesity. N Engl J Med. 2025, 392:427-37. 10.1056\/NEJMoa2410027","journal-title":"N Engl J Med"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.124.072679","article-title":"Effects of tirzepatide on the clinical trajectory of patients with heart failure, preserved ejection fraction, and obesity","volume":"151","author":"Zile MR","year":"2025","unstructured":"Zile MR, Borlaug BA, Kramer CM, et al.. Effects of tirzepatide on the clinical trajectory of patients with heart failure, preserved ejection fraction, and obesity. Circulation. 2025, 151:656-68. 10.1161\/CIRCULATIONAHA.124.072679","journal-title":"Circulation"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2024.08.028","article-title":"Inflammation in obesity-related HFpEF: the step-HFpEF program","volume":"84","author":"Verma S","year":"2024","unstructured":"Verma S, Petrie MC, Borlaug BA, et al.. Inflammation in obesity-related HFpEF: the step-HFpEF program. J Am Coll Cardiol. 2024, 84:1646-62. 10.1016\/j.jacc.2024.08.028","journal-title":"J Am Coll Cardiol"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2024.08.021","article-title":"Effect of semaglutide on cardiac structure and function in patients with obesity-related heart failure","volume":"84","author":"Solomon SD","year":"2024","unstructured":"Solomon SD, Ostrominski JW, Wang X, et al.. Effect of semaglutide on cardiac structure and function in patients with obesity-related heart failure. J Am Coll Cardiol. 2024, 84:1587-602. 10.1016\/j.jacc.2024.08.021","journal-title":"J Am Coll Cardiol"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2024.11.001","article-title":"Tirzepatide reduces LV mass and Paracardiac adipose tissue in obesity-related heart failure: SUMMIT CMR substudy","volume":"85","author":"Kramer CM","year":"2025","unstructured":"Kramer CM, Borlaug BA, Zile MR, et al.. Tirzepatide reduces LV mass and Paracardiac adipose tissue in obesity-related heart failure: SUMMIT CMR substudy. J Am Coll Cardiol. 2025, 85:699-706. 10.1016\/j.jacc.2024.11.001","journal-title":"J Am Coll Cardiol"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-024-03374-z","article-title":"Effects of tirzepatide on circulatory overload and end-organ damage in heart failure with preserved ejection fraction and obesity: a secondary analysis of the SUMMIT trial","volume":"31","author":"Borlaug BA","year":"2025","unstructured":"Borlaug BA, Zile MR, Kramer CM, et al.. Effects of tirzepatide on circulatory overload and end-organ damage in heart failure with preserved ejection fraction and obesity: a secondary analysis of the SUMMIT trial. Nat Med. 2025, 31:544-51. 10.1038\/s41591-024-03374-z","journal-title":"Nat Med"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.2337\/dbi20-0049","article-title":"Cardiovascular effects of incretin-based therapies: integrating mechanisms with cardiovascular outcome trials","volume":"71","author":"Ussher JR","year":"2022","unstructured":"Ussher JR, Greenwell AA, Nguyen MA, Mulvihill EE. Cardiovascular effects of incretin-based therapies: integrating mechanisms with cardiovascular outcome trials. Diabetes. 2022, 71:173-83. 10.2337\/dbi20-0049","journal-title":"Diabetes"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/498311-incretin-based-therapies-in-obesity-related-heart-failure-with-preserved-ejection-fraction-hfpef-a-systematic-review-of-emerging-cardiometabolic-disease-modification-beyond-glycemic-control","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,31]],"date-time":"2026-05-31T07:09:33Z","timestamp":1780211373000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/498311-incretin-based-therapies-in-obesity-related-heart-failure-with-preserved-ejection-fraction-hfpef-a-systematic-review-of-emerging-cardiometabolic-disease-modification-beyond-glycemic-control"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,31]]},"references-count":20,"URL":"https:\/\/doi.org\/10.7759\/cureus.109953","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5,31]]}}}